Emyria Ltd has released a press release.
Pax Centre Acquisition to Advance Psychedelic Therapies
Filed with ASX ·
6ix hasn’t read this filing yet.
In the deck
Story so far
Earlier from Emyria
- Emyria hails ethics approval for MDMA-assisted clinical trial
- Emyria Receives Ethics Approval for MDMA-assisted Therapy
- Emyria Completes $2.5m Placement
- March 2023 Quarterly Activities Report and Appendix 4C
- Emyria launches new high potency Ultra-Pure CBD capsule
Later from Emyria
- Presentation - Pax Acquisition and Company Update
- Emyria Recruits First Patient MDMA-Assisted Therapy Trial
- June 2023 Quarterly Activities Report and Appendix 4C
- Emyria advances development and commercialisation of unique drug products
- Emyria Launches Ketamine-Assisted Therapy Program
Follow Emyria into a list and get an email when it puts out news.
Follow Emyria